Terms: = Uterine cancer AND WFDC2, EDDM4, HE4, WAP5, dJ461P17.6
131 results:
1. Effect of 3D laparoscopy versus traditional laparotomy on serum tumor markers and coagulation function in patients with early-stage endometrial cancer.
Chen H; Xu D; Yu Y; Huang J; Zhou Q; Wang Q
Clinics (Sao Paulo); 2024; 79():100337. PubMed ID: 38368841
[TBL] [Abstract] [Full Text] [Related]
2. Combination of serum CST1 and he4 for early diagnosis of endometrial cancer.
Zhong W; Liu Y; Zhang L; Zhuang W; Chen J; Huang Z; Zheng Y; Huang Y
PeerJ; 2023; 11():e16424. PubMed ID: 38077439
[TBL] [Abstract] [Full Text] [Related]
3. Development and validation of prediction model for early warning of ovarian metastasis risk of endometrial carcinoma.
Zhao Q; Li Y; Wang T
Medicine (Baltimore); 2023 Oct; 102(41):e35439. PubMed ID: 37832099
[TBL] [Abstract] [Full Text] [Related]
4. Effects of coagulation function indicators and tumor markers on diagnosis and clinicopathological characteristics of endometrial cancer.
Li H; Liao H; Jing B; Wang Y
Int J Biol Markers; 2023 Dec; 38(3-4):214-222. PubMed ID: 37635376
[TBL] [Abstract] [Full Text] [Related]
5. Diagnostic value of serum human epididymis protein 4, carbohydrate antigen 125 and their combination in endometrial cancer: A meta-analysis.
Wu Q; Bai SN; Song LY; Wu WF; Han LN
Medicine (Baltimore); 2023 Aug; 102(33):e34737. PubMed ID: 37603503
[TBL] [Abstract] [Full Text] [Related]
6. An analysis of clinical characteristics and prognosis of endometrioid ovarian cancer based on the SEER database and two centers in China.
Chen S; Lu H; Jiang S; Li M; Weng H; Zhu J; Zhang T; Wang Y; Zhao W; Wu D; Shen Z; Yang Z; Zhou Y
BMC Cancer; 2023 Jul; 23(1):608. PubMed ID: 37391693
[TBL] [Abstract] [Full Text] [Related]
7. Endometrioid adenocarcinoma: combined multiparametric MRI and tumour marker he4 to evaluate tumour grade and lymphovascular space invasion.
Yue XN; He XY; Wu JJ; Fan W; Zhang HJ; Wang CW
Clin Radiol; 2023 Aug; 78(8):e574-e581. PubMed ID: 37183140
[TBL] [Abstract] [Full Text] [Related]
8. Serum expression of tumor marker CA242 in patients with different gynecological diseases.
Zhu J; Li H
Lab Med; 2023 Nov; 54(6):613-617. PubMed ID: 37035887
[TBL] [Abstract] [Full Text] [Related]
9. Serum lipidomic profiling by UHPLC-MS/MS may be able to detect early-stage endometrial cancer.
Cheng F; Fan W; Gui L; Liu Y; Ling Y; Huang R; Wen Z; Chen Y
Anal Bioanal Chem; 2023 Apr; 415(10):1841-1854. PubMed ID: 36799979
[TBL] [Abstract] [Full Text] [Related]
10. Detection of Circulating Tumor Cell-Related Markers in Gynecologic cancer Using Microfluidic Devices: A Pilot Study.
Law KS; Huang CE; Chen SW
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768623
[TBL] [Abstract] [Full Text] [Related]
11. Serum he4 predicts progestin treatment response in endometrial cancer and atypical hyperplasia: A prognostic study.
Barr CE; Sergeant JC; Agnew HJ; Bolton J; McVey RJ; Crosbie EJ
BJOG; 2023 Jul; 130(8):941-948. PubMed ID: 36715558
[TBL] [Abstract] [Full Text] [Related]
12. The Utility of Preoperative Serum CA125 Combined with he4 to Predict Lymph Node Metastasis in Endometrial cancer.
Prueksaritanond N; Angsathapon S; Insin P
Gynecol Obstet Invest; 2023; 88(1):53-60. PubMed ID: 36596280
[TBL] [Abstract] [Full Text] [Related]
13. Evaluation of he4 as a prognostic biomarker in uterine cervical cancer
Dubey H; Ranjan A; Durai J; Khan MA; Lakshmy R; Khurana S; Gupta S; Meena J; Ray MD; Tanwar P; Chopra A; Tiwari S
Cancer Treat Res Commun; 2023; 34():100672. PubMed ID: 36525756
[TBL] [Abstract] [Full Text] [Related]
14. he4 Tissue Expression as A Putative Prognostic Marker in Low-Risk/Low-Grade Endometrioid Endometrial cancer: A Review.
Mais V; Fais ML; Peiretti M; Fanni D; Massa E; Carboni G; Fais G; Deo G; Angioni S
Curr Oncol; 2022 Nov; 29(11):8540-8555. PubMed ID: 36354733
[TBL] [Abstract] [Full Text] [Related]
15. Relationship between 18F-fluorodeoxyglucose PET/computed tomography metabolic parameters and clinicopathology in endometrial cancer.
Yao X; Tan X; Zhang H; Yuan H; Zeng B; He L; Jiang L
Nucl Med Commun; 2022 Dec; 43(12):1233-1238. PubMed ID: 36345768
[TBL] [Abstract] [Full Text] [Related]
16. A Rehabilitation Model Conducive to Postoperative Recovery of Endometrial cancer Patients after Laparoscopy.
Yang L; Han F
Biomed Res Int; 2022; 2022():9910841. PubMed ID: 36093393
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic values of human epididymis protein 4 expression in patients with endometrial cancer: A systematic review and meta-analysis.
Han LN; Han YW; Yan P
J Obstet Gynaecol Res; 2022 Sep; 48(9):2255-2269. PubMed ID: 35844088
[TBL] [Abstract] [Full Text] [Related]
18. Comparison between Pelvic IMRT and 3D-CRT in Combination with Chemotherapy via Nrf2 Expression on the High-Risk Endometrial cancer.
Wang N; Zhang X; Xu S; Li X; Meng Y; Dou Z
Cell Mol Biol (Noisy-le-grand); 2022 Feb; 67(6):267-273. PubMed ID: 35818187
[TBL] [Abstract] [Full Text] [Related]
19. Prediction of early recurrencies of uterine body cancer based on monitoring of serum biological markers.
Kovalenko NV; Verenikina EV; Maksimov AY; Gladkikh ON; Demidova AA; Domashenko EV
Klin Lab Diagn; 2022 Apr; 67(4):197-203. PubMed ID: 35575391
[TBL] [Abstract] [Full Text] [Related]
20. Serum Human Epididymis Protein 4 as a Prognostic Marker in Cervical cancer.
Hwang WY; Suh DH; Kim K; Kim YB; No JH
Cancer Control; 2022; 29():10732748221097778. PubMed ID: 35506739
[TBL] [Abstract] [Full Text] [Related]
[Next]
